We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Molecular Templates Inc | NASDAQ:MTEM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.66 | 1.64 | 1.72 | 0 | 09:03:22 |
From May 2021 to May 2024
By Colin Kellaher
Molecular Templates Inc. on Monday said Vertex Pharmaceuticals Inc. is terminating a 2019 collaboration aimed at developing conditioning agents for applications aimed at enhancing the hematopoietic stem cell transplant process.
Molecular, an Austin, Texas, clinical-stage biopharmaceutical company, said the termination is effective Oct. 29.
Under the 2019 agreement, Boston drug maker Vertex made a $38 million upfront payment to Molecular, which was also eligible for future milestone and option payments of up to $522 million.
As part of the collaboration, Molecular was developing engineered toxin bodies for myeloablation, an indication separate from its core focus on cancer therapeutics.
Shares of Molecular Templates fell 2.8%, to $6.16, in early trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 18, 2021 10:27 ET (14:27 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Molecular Templates Chart |
1 Month Molecular Templates Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
